MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial.
Saved in:
| Title: | MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial. |
|---|---|
| Authors: | Chung L (AUTHOR), Shapiro L (AUTHOR), Fiorentino D (AUTHOR), Baron M (AUTHOR), Shanahan J (AUTHOR), Sule S (AUTHOR), Hsu V (AUTHOR), Rothfield N (AUTHOR), Steen V (AUTHOR), Martin RW (AUTHOR), Smith E (AUTHOR), Mayes M (AUTHOR), Simms R (AUTHOR), Pope J (AUTHOR), Kahaleh B (AUTHOR), Csuka ME (AUTHOR), Gruber B (AUTHOR), Collier D (AUTHOR), Sweiss N (AUTHOR), Gilbert A (AUTHOR) |
| Source: | Arthritis & Rheumatism. Mar2009, Vol. 60 Issue 3, p870-877. 8p. |
| Database: | Academic Search Ultimate |
| ISSN: | 00043591 |
|---|---|
| DOI: | 10.1002/art.24351 |
